[Form 4] Viemed Healthcare, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jerome Cambre, Vice President of Sales at Viemed Healthcare, Inc. (VMD), reported two open-market sales of common shares on 08/13/2025. He sold 1,580 shares at $7.33 and 3,300 shares at $7.32, a total of 4,880 shares. Following these transactions his beneficial ownership is reported as 84,191 shares. The filing was signed by an attorney-in-fact on 08/14/2025. No derivative securities were reported on this Form 4.

Positive

• Timely disclosure of insider transactions filed and signed
• No derivative transactions reported on this Form 4

Negative

• Insider sold 4,880 shares across two transactions on 08/13/2025
• Sales executed at ~$7.32–$7.33, reducing beneficial ownership to 84,191 shares

Insights

Financial Analyst

TL;DR: Routine open-market insider sales totaling 4,880 shares; transaction sizes and prices are disclosed without derivatives.

The filing shows two discrete sales by a named officer, with specific share counts and prices that reduce his reported holdings to 84,191 shares. These are outright disposals of common stock, not part of any disclosed derivative exercise or 10b5-1 plan on the face of this Form 4. For investors this is a transparency item rather than an immediate indicator of company performance because the filing does not state purpose, proceeds use, or any connected corporate developments.

Corporate Governance Expert

TL;DR: The insider sale is documented and signed by an attorney-in-fact; no governance red flags are evident from the filing alone.

This Form 4 reports timely disclosure of open-market sales by an officer and contains a signature by an authorized attorney-in-fact. There are no amendments, option exercises, or indirect ownership notes included. Absent additional context (e.g., scheduled trading plan, corporate events, or concurrent insider activity), the transaction appears to be a routine reporting of disposition rather than a governance concern.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cambre Jerome

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President of Sales

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/13/2025		S		1,580	D	$7.33	87,491	D
Common Shares	08/13/2025		S		3,300	D	$7.32	84,191	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Viemed Healthcare insider Jerome Cambre report on Form 4 (VMD)?

He reported two open-market sales on 08/13/2025: 1,580 shares at $7.33 and 3,300 shares at $7.32, totaling 4,880 shares.

How many shares does Jerome Cambre beneficially own after the reported transactions?

The Form 4 reports 84,191 common shares beneficially owned following the transactions.

Were any derivative securities reported by the insider in this filing?

No. Table II shows no derivative securities acquired, disposed of, or beneficially owned in this Form 4.

Who signed the Form 4 and when was it signed?

The filing shows a signature by Jesse Bergeron, Attorney-in-Fact dated 08/14/2025.

Does the Form 4 state the reason for the share sales or a 10b5-1 plan?

No. The document does not state a reason for the sales and does not indicate that the transactions were part of a 10b5-1 plan.

Is this filing an amendment or the original Form 4?

The form does not indicate an amendment date; fields show the transaction date as 08/13/2025 and the signature date as 08/14/2025.